Earnings Call · Q2 FY2025·2025-08-12

Q2 25EPS -41.94%·Rev n/aQ1 25EPS -54.47%·Rev n/aQ4 24EPS -12.82%·Rev n/aQ3 24EPS +12.12%·Rev n/a⚠ consensus missing

ALX ONCOLOGY HOLDINGS INC ALXO

Jason W. Lettmann — Chief Executive Officer

Alan Bart Sandler — Chief Medical Officer

Harish Shantharam — Chief Development Officer

+7.4%1d on move date+7.1% vs SPY3d+4.7%5d+44.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ALXO calls or request research access.

More ALXO calls Browse calls Request research access